Search

M2 EQUITYBITES-April 1, 2019-The US FDA authorises new oral treatment Mavenclad for multiple sclerosis (C)2019 M2 COMMUNICATIONS http://www.m2.com Public health agency the US Food and Drug Administration stated on Friday [...]

M2 PHARMA-April 1, 2019-The US FDA authorises new oral treatment Mavenclad for multiple sclerosis (C)2019 M2 COMMUNICATIONS Public health agency the US Food and Drug Administration stated on Friday that [...]

Darmstadt: Merck has issued the following news release: Merck, a leading science and technology company, today announced that the Argentinian Administration of Medicines, Food and Medical Technology (ANMAT), has approved [...]

DARMSTADT: Merck has issued the following news release: Merck, a leading science and technology company, today announced that the Argentinian Administration of Medicines, Food and Medical Technology (ANMAT), has approved [...]

DARMSTADT, Germany, February 26, 2018 /PRNewswire/ -- Not intended for U.K./U.S. based media First oral short-course treatment for highly active relapsing multiple sclerosis (RMS) now approved in Argentina Mavenclad has [...]

DUBLIN: Research and Markets has issued the following news release: The 'Drug Analysis: Mavenclad' drug pipelines has been added to ResearchAndMarkets.com's offering. Mavenclad contains cladribine, a small molecule that suppresses [...]

DUBLIN -- The 'Drug Analysis: Mavenclad' drug pipelines has been added to ResearchAndMarkets.com's offering. Mavenclad contains cladribine, a small molecule that suppresses the immune system by selectively targeting lymphocytes, which [...]

M2 PRESSWIRE-February 15, 2018-: 2017 Mavenclad Drug Analysis: A Small Molecule that Suppresses the Immune System by Selectively Targeting Lymphocytes (C)1994-2018 M2 COMMUNICATIONS RDATE:15022018 The 'Drug Analysis: Mavenclad' drug pipelines [...]

Voluntary ex ante transparency notice: Supply of cladribine (mavenclad) ( united kingdom-edinburgh: Pharmaceutical products nd ) date of contract award: 16/01/2018 Total value of the contract/lot/concession: 5 750 000.00 GBP [...]

Contract awarded for Supply of Cladribine (Mavenclad) Contractor name : THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) ('NSS') Contractor address : Gyle Square (Nss Head [...]

ENPNewswire-December 8, 2017--Merck's Mavenclad Approved for Relapsing-Remitting Multiple Sclerosis in Canada (C)2017 ENPublishing - http://www.enpublishing.co.uk Release date- 06122017 - Merck, a leading science and technology company, today announced that Health [...]

Darmstadt: Merck has issued the following news release: First oral short-course treatment for relapsing- remitting multiple sclerosis (RRMS) now approved in Canada, which has one of the highest rates of [...]

DARMSTADT: Merck has issued the following news release: First oral short-course treatment for relapsing- remitting multiple sclerosis (RRMS) now approved in Canada, which has one of the highest rates of [...]

DARMSTADT, Germany, December 4, 2017 /PRNewswire/ -- First oral short-course treatment for relapsing- remitting multiple sclerosis (RRMS) now approved in Canada, which has one of the highest rates of MS [...]

Contract award notice: Framework agreement for the purchase of mavenclad (cladribin) 2017 - in1.218.a. (denmark-copenhagen: Pharmaceutical products) : The purpose of the framework agreement is to provide the hospital pharmacies [...]

Darmstadt: Merck has issued the following news release: First multiple sclerosis (MS) therapy to achieve positive NICE recommendation in the shortest possible timeframe Mavenclad has shown sustained clinical efficacy up [...]

DARMSTADT, Germany, November 9, 2017 /PRNewswire/ -- First multiple sclerosis (MS) therapy to achieve positive NICE recommendation in the shortest possible timeframe Mavenclad has shown sustained clinical efficacy up to [...]

Darmstadt: Merck has issued the following news release: Data suggest Mavenclad may significantly increase proportion of patients exhibiting no evidence of disease activity versus placebo Analysis of 10,000 patient years [...]

SCOTTSDALE: Meritage Homes Corporation has issued the following news release: Not intended for US/UK based media Important safety and immune cell analyses further characterise the selective immune reconstitution approach of [...]

Brussels: Public Register European Parliament has issued the following document: For Comitology Register OVERALL VOTING RESULT ON A FORMAL OPINION Related to draft implementing acts submitted under Regulation (EU) No [...]

Darmstadt, Germany: MERCK KGAA has issued the following press release: Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the European Commission (EC) has granted marketing [...]

ENPNewswire-August 28, 2017--Merck - European Commission Grants Approval for Mavenclad (C)2017 ENPublishing - http://www.enpublishing.co.uk Release date- 25082017 - Darmstadt, Germany - Merck, a leading science and technology company, today announced [...]

DARMSTADT: Merck has issued the following news release: First oral short-course treatment for highly active relapsing multiple sclerosis (RMS)[1] now approved in Europe MAVENCLAD(r) has shown sustained clinical efficacy for [...]

The European Commission has approved cladribine 10-mg tablets (Mavenclad, Merck KGaA) for the treatment of highly active relapsing multiple sclerosis (RMS) as defined by clinical or imaging features, the company [...]

Aug 25, 2017 (M2 EQUITYBITES via COMTEX) -- Science and technology company Merck reported on Thursday the receipt of the European Commission's(EC) marketing authorisation for MAVENCLAD 10mg (Cladribine Tablets) for [...]

M2 PHARMA-March 2, 2018-Argentinian Regulatory Agency Grants Approval for Mavenclad (Cladribine Tablets) for Treatment of Relapsing MS (C)2018 M2 COMMUNICATIONS - Darmstadt, Germany-based science and technology company Merck KGaA has [...]

M2 PHARMA-December 4, 2017-Merck passes Health Canada's approval for MAVENCLAD (Cladribine Tablets) to treat relapsing-remitting multiple sclerosis (C)2017 M2 COMMUNICATIONS Healthcare company Merck reported on Friday the receipt of Health [...]

M2 EQUITYBITES-December 4, 2017-Merck passes Health Canada's approval for MAVENCLAD (Cladribine Tablets) to treat relapsing-remitting multiple sclerosis (C)2017 M2 COMMUNICATIONS http://www.m2.com Healthcare company Merck reported on Friday the receipt of [...]

M2 PHARMA-August 28, 2017-European Commission grants marketing authorisation to Merck's MAVENCLAD (C)2017 M2 COMMUNICATIONS It was reported on Friday that the European Commission has granted marketing authorisation to Merck, a [...]

M2 EQUITYBITES-August 28, 2017-European Commission grants marketing authorisation to Merck's MAVENCLAD (C)2017 M2 COMMUNICATIONS http://www.m2.com It was reported on Friday that the European Commission has granted marketing authorisation to Merck, [...]

M2 PHARMA-August 25, 2017-Merck's Mavenclad gets EU approval as a treatment for MS (C)2017 M2 COMMUNICATIONS The European Commission (EC) has approved Merck Group's Mavenclad (cladribine) as a treatment for [...]

M2 EQUITYBITES-August 25, 2017-Merck's Mavenclad gets EU approval as a treatment for MS (C)2017 M2 COMMUNICATIONS http://www.m2.com The European Commission (EC) has approved Merck Group's Mavenclad (cladribine) as a treatment [...]

M2 PHARMA-August 25, 2017-Merck passes European Commission's approval for Mavenclad for treating highly active relapsing multiple sclerosis in the EU (C)2017 M2 COMMUNICATIONS Science and technology company Merck reported on [...]

M2 EQUITYBITES-August 25, 2017-Merck passes European Commission's approval for Mavenclad for treating highly active relapsing multiple sclerosis in the EU (C)2017 M2 COMMUNICATIONS http://www.m2.com Science and technology company Merck reported [...]

Merck's Mavenclad is being backed by the National Institute for Health and Clinical Excellence as an option for treating highly active multiple sclerosis in adults on the NHS. For the [...]